According to Ars Technica, the cost of the low-priced auto-injector pens is similar to the price of the EpiPens before Mylan bought the rights to the product back in 2007.
Mylan drew widespread criticism from consumers and Congress when it raised the price of a two-pack of EpiPens to over $600. Then, in August 2016, Mylan announced they were coming out with a generic version of their EpiPen two-pack that would cost just $300.
Critics accused the Canonsburg, Penn. drugmaker of price gouging, a charge rejected by Mylan CEO Heather Bresch, who blamed the controversy on health insurers.
And another surprise announcement was made on Wednesday, with Cigna, one of the country’s top health insurers saying they will no longer provide coverage of the EpiPen and would cover only the half-priced generic versions, according to WTVR News Richmond. A CVS spokeswoman said the CVS price cut for the generic Adrenaclick pen was not related to the Cigna announcement.
Adrenaclick and EpiPen both give an emergency injection of epinephrine to treat life-threatening allergic reactions that can send a person into anaphylactic shock.
And according to CNN Money, on Wednesday, during a press conference, President-elect Donald Trump vowed to fight against price hikes by drug companies, saying they were “getting away with murder.” Mylan’s stock prices dropped more than four percent.
